156 related articles for article (PubMed ID: 38497774)
21. Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Ishii H; Azuma K; Sakai K; Naito Y; Matsuo N; Tokito T; Yamada K; Hoshino T; Nishio K
Sci Rep; 2020 Jan; 10(1):691. PubMed ID: 31959859
[TBL] [Abstract][Full Text] [Related]
22. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment?
Lin JZ; Ma SK; Wu SX; Yu SH; Li XY
Medicine (Baltimore); 2018 Jul; 97(30):e11569. PubMed ID: 30045282
[TBL] [Abstract][Full Text] [Related]
23. Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.
Roper N; El Meskini R; Maity T; Atkinson D; Day A; Pate N; Cultraro CM; Pack S; Zgonc V; Weaver Ohler Z; Guha U
Cancer Res Commun; 2024 Feb; 4(2):337-348. PubMed ID: 38276867
[TBL] [Abstract][Full Text] [Related]
24. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
[TBL] [Abstract][Full Text] [Related]
25. Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting.
Kwok WC; Ho JCM; Tam TCC; Ip MSM; Lam DCL
Thorac Cancer; 2022 Jul; 13(14):2057-2063. PubMed ID: 35668712
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
27. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
[TBL] [Abstract][Full Text] [Related]
28. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.
Takahashi A; Seike M; Chiba M; Takahashi S; Nakamichi S; Matsumoto M; Takeuchi S; Minegishi Y; Noro R; Kunugi S; Kubota K; Gemma A
Sci Rep; 2018 Oct; 8(1):14896. PubMed ID: 30291293
[TBL] [Abstract][Full Text] [Related]
29. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive
Takeda M; Nakagawa K
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609789
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review.
Nargesi S; Dolatshahi Z; Rezapour A; Alipour V; Souresrafil A; Farabi H; Javadmoosavi SA; Safakhah M; Moradi N
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):543-554. PubMed ID: 34846235
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer.
Rossi A; Muscarella LA; Di Micco C; Carbonelli C; D'alessandro V; Notarangelo S; Palomba G; Sanpaolo G; Taurchini M; Graziano P; Maiello E
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1281-1288. PubMed ID: 29095090
[TBL] [Abstract][Full Text] [Related]
32. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
34. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Popat S; Jung HA; Lee SY; Hochmair MJ; Lee SH; Escriu C; Lee MK; Migliorino MR; Lee YC; Girard N; Daoud H; Märten A; Miura S
Lung Cancer; 2021 Dec; 162():9-15. PubMed ID: 34649106
[TBL] [Abstract][Full Text] [Related]
35. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Xiong X; Zhang Y; Wang Z; Zhou C; Yang P; Du X; Yang L; Liu W
Clin Chim Acta; 2022 Feb; 527():1-10. PubMed ID: 34999058
[TBL] [Abstract][Full Text] [Related]
37. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T
Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820
[TBL] [Abstract][Full Text] [Related]
38. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
[TBL] [Abstract][Full Text] [Related]
39. Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Vaid AK; Gupta A; Momi G
Int J Oncol; 2021 Feb; 58(2):171-184. PubMed ID: 33491758
[TBL] [Abstract][Full Text] [Related]
40. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A; Wang J; Wang Y; Lee SH; Melosky B; Shih JY; Wang J; Azuma K; Juan-Vidal O; Cobo M; Felip E; Girard N; Cortot AB; Califano R; Cappuzzo F; Owen S; Popat S; Tan JL; Salinas J; Tomasini P; Gentzler RD; William WN; Reckamp KL; Takahashi T; Ganguly S; Kowalski DM; Bearz A; MacKean M; Barala P; Bourla AB; Girvin A; Greger J; Millington D; Withelder M; Xie J; Sun T; Shah S; Diorio B; Knoblauch RE; Bauml JM; Campelo RG; Cho BC;
Ann Oncol; 2024 Jan; 35(1):77-90. PubMed ID: 37879444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
